PL3083605T3 - Związki fluorofenylopirazolowe - Google Patents

Związki fluorofenylopirazolowe

Info

Publication number
PL3083605T3
PL3083605T3 PL14827909T PL14827909T PL3083605T3 PL 3083605 T3 PL3083605 T3 PL 3083605T3 PL 14827909 T PL14827909 T PL 14827909T PL 14827909 T PL14827909 T PL 14827909T PL 3083605 T3 PL3083605 T3 PL 3083605T3
Authority
PL
Poland
Prior art keywords
fluorophenyl
pyrazol compounds
pyrazol
compounds
fluorophenyl pyrazol
Prior art date
Application number
PL14827909T
Other languages
English (en)
Inventor
Kevin Kun-Chin Liu
Liang Wu
Yinong Xie
Guoqiang ZHOU
Original Assignee
Eli Lilly & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly & Company filed Critical Eli Lilly & Company
Publication of PL3083605T3 publication Critical patent/PL3083605T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL14827909T 2013-12-19 2014-12-11 Związki fluorofenylopirazolowe PL3083605T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2013/089987 WO2015089800A1 (en) 2013-12-19 2013-12-19 Fluorophenyl pyrazol compounds
EP14827909.4A EP3083605B1 (en) 2013-12-19 2014-12-11 Fluorophenyl pyrazol compounds
PCT/US2014/069785 WO2015094913A1 (en) 2013-12-19 2014-12-11 Fluorophenyl pyrazol compounds

Publications (1)

Publication Number Publication Date
PL3083605T3 true PL3083605T3 (pl) 2018-07-31

Family

ID=52355187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14827909T PL3083605T3 (pl) 2013-12-19 2014-12-11 Związki fluorofenylopirazolowe

Country Status (23)

Country Link
US (1) US9499490B2 (pl)
EP (1) EP3083605B1 (pl)
JP (1) JP6190067B2 (pl)
KR (1) KR101827660B1 (pl)
CN (1) CN105814039B (pl)
AU (1) AU2014366436B2 (pl)
BR (1) BR112016011778A8 (pl)
CA (1) CA2929563C (pl)
DK (1) DK3083605T3 (pl)
EA (1) EA029058B1 (pl)
ES (1) ES2664418T3 (pl)
HR (1) HRP20180618T1 (pl)
HU (1) HUE039102T2 (pl)
LT (1) LT3083605T (pl)
MX (1) MX2016007985A (pl)
NO (1) NO3083605T3 (pl)
PL (1) PL3083605T3 (pl)
PT (1) PT3083605T (pl)
RS (1) RS57071B1 (pl)
SA (1) SA516371323B1 (pl)
SI (1) SI3083605T1 (pl)
TR (1) TR201802981T4 (pl)
WO (2) WO2015089800A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
WO2016131198A1 (en) * 2015-02-18 2016-08-25 Eli Lilly And Company Pyrazole compounds
WO2016201662A1 (en) * 2015-06-18 2016-12-22 Eli Lilly And Company Fluoropyridyl pyrazol compounds
CN109096194B (zh) * 2018-10-09 2022-02-08 湖南师范大学 一种双胍衍生物、药物组合物、制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223932A4 (en) * 1999-10-01 2003-01-15 Smithkline Beecham Corp COMPOUNDS AND METHODS
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002078699A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
JP2005508951A (ja) * 2001-10-12 2005-04-07 スミスクライン・ビーチャム・コーポレイション 化合物および方法
AU2002359694A1 (en) * 2001-12-14 2003-06-30 Smithkline Beecham Corporation Compounds and methods
EP1601666A2 (en) 2002-07-02 2005-12-07 Schering Corporation New neuropeptide y y5 receptor antagonists
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
DE102004049078A1 (de) * 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
US20120010290A1 (en) * 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
TW201245155A (en) 2010-09-01 2012-11-16 Du Pont Fungicidal pyrazoles
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
US9062028B2 (en) * 2011-04-28 2015-06-23 Bristol-Myers Squibb Company Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول

Also Published As

Publication number Publication date
BR112016011778A8 (pt) 2018-01-30
TR201802981T4 (tr) 2018-03-21
NO3083605T3 (pl) 2018-07-21
CA2929563A1 (en) 2015-06-25
CN105814039A (zh) 2016-07-27
DK3083605T3 (en) 2018-03-12
EP3083605B1 (en) 2018-02-21
EA201690924A1 (ru) 2016-09-30
WO2015089800A1 (en) 2015-06-25
BR112016011778A2 (pt) 2017-08-08
KR20160075827A (ko) 2016-06-29
KR101827660B1 (ko) 2018-02-08
LT3083605T (lt) 2018-04-10
SI3083605T1 (en) 2018-04-30
HUE039102T2 (hu) 2018-12-28
US20160289195A1 (en) 2016-10-06
PT3083605T (pt) 2018-03-01
EA029058B1 (ru) 2018-02-28
EP3083605A1 (en) 2016-10-26
ES2664418T3 (es) 2018-04-19
WO2015094913A1 (en) 2015-06-25
MX2016007985A (es) 2016-09-09
SA516371323B1 (ar) 2018-04-24
CN105814039B (zh) 2018-07-17
AU2014366436A1 (en) 2016-05-19
HRP20180618T1 (hr) 2018-07-13
RS57071B1 (sr) 2018-06-29
CA2929563C (en) 2018-05-15
JP2016540801A (ja) 2016-12-28
AU2014366436B2 (en) 2017-08-24
US9499490B2 (en) 2016-11-22
JP6190067B2 (ja) 2017-08-30

Similar Documents

Publication Publication Date Title
ZA201505397B (en) Novel pyrazole derivative
GB201309085D0 (en) Compounds
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
IL240327B (en) New pyrazole derivatives
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
ZA201507044B (en) Pyridinylpyrazoloquinoline compound
GB201317619D0 (en) Compounds
GB201319363D0 (en) Compounds
GB201320636D0 (en) Compounds
GB201311953D0 (en) Compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201312901D0 (en) Compounds
HUE039102T2 (hu) Fluorfenil-pirazol vegyületek
EP2948457A4 (en) COMPOUNDS
GB201306794D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201318461D0 (en) Compounds
GB201316014D0 (en) Compounds
GB201321283D0 (en) Compounds
GB201318323D0 (en) Compounds
GB201318143D0 (en) Compounds
GB201317118D0 (en) Compounds
GB201316717D0 (en) Compounds